ACTH Administration: Diagnostic Testing and Infantile Spasms Treatment
For Adrenal Stimulation Testing
The standard corticotropin stimulation test should be performed using 250 µg of synthetic ACTH (cosyntropin) administered as an intravenous or intramuscular bolus, with cortisol measured at baseline and 30 or 60 minutes post-injection 1. This represents the diagnostic gold standard for primary adrenal insufficiency.
Diagnostic Protocol
- Baseline sampling: Draw two blood samples 15 minutes before and immediately prior to ACTH administration; average these for baseline values 2
- Dosing: Administer 250 µg ACTH as IV bolus over 30-60 seconds (or IM) 1
- Post-administration sampling: Draw blood at 15,30, and 60 minutes after administration 2
- Interpretation cutoffs:
Important caveat: The 1 µg low-dose test does not provide better diagnostic accuracy than the standard 250 µg test and is not recommended 1.
For Cushing's Syndrome Differentiation
When differentiating pituitary from ectopic ACTH production, use corticorelin (CRH) 1 µg/kg IV over 30-60 seconds 2. Pituitary Cushing's disease typically shows exaggerated ACTH/cortisol responses (mean +227% increase), while ectopic ACTH secretion shows minimal response (mean +15% increase) 2.
For Infantile Spasms Treatment
Low-dose ACTH (20-30 IU/day for 2-6 weeks) should be used as first-line treatment for infantile spasms, as it is equally effective as high-dose regimens but with fewer adverse effects 4. This recommendation is based on evidence showing no significant difference in response rates between high-dose (150 U/m²/day) and low-dose (20-30 IU/day) protocols.
Treatment Protocol
Dosing regimen:
- Initial dose: 20-30 IU/day (or 0.02 mg/kg/day tetracosactide depot) 5, 6
- Duration: 2-6 weeks of treatment 7, 4
- Tapering: Taper over 1 week after treatment period 7
Response assessment:
- Evaluate at 2-3 weeks for cessation of spasms and resolution of hypsarrhythmia on EEG 6, 7
- Response rates: 50-58% achieve complete cessation of spasms 7
- Low-dose synthetic ACTH (tetracosactide) is equally effective as natural ACTH 6
Critical Monitoring Parameters
During treatment:
- Blood pressure monitoring (hypertension risk increases with higher initial doses) 8
- Weight and growth parameters
- Signs of infection (respiratory complications are common) 8
- Cushingoid features
Post-treatment adrenal assessment:
- Contrary to older concerns, adrenal suppression is uncommon after standard ACTH treatment for infantile spasms 9. However, for long-term ACTH therapy (>3 months), perform CRH stimulation testing to assess adrenal function 10
- Consider hydrocortisone stress coverage if peak cortisol <15 µg/dL on stimulation testing during prolonged therapy 10
Key Clinical Pearls
Timing matters for outcomes: Shorter lag time from spasm onset to ACTH initiation improves long-term developmental outcomes 4. Don't delay treatment while pursuing extensive workup.
ACTH vs Vigabatrin: ACTH is more effective than vigabatrin for short-term spasm control in non-tuberous sclerosis cases 4. For cryptogenic infantile spasms specifically, hormonal therapy (ACTH or prednisolone) leads to better developmental outcomes than vigabatrin 4.
Dose-related adverse effects: The risk of hypertension correlates directly with initial ACTH dosing (particularly initial doses >20 IU and initial average doses >2.5 IU/kg) 8. Start with lower doses to minimize this risk, as efficacy is equivalent.
Synthetic vs natural ACTH: No difference in efficacy exists between synthetic tetracosactide and natural ACTH formulations 6. Use whichever is available and affordable.
Common Pitfalls to Avoid
- Don't use high-dose protocols unnecessarily: The historical 150 U/m²/day regimen offers no advantage over 20-30 IU/day but increases hypertension risk 7, 8
- Don't assume adrenal suppression requires routine testing: Standard 2-6 week courses rarely cause clinically significant adrenal insufficiency 9. Reserve hormonal testing for patients requiring >3 months of therapy 10
- Don't continue ineffective treatment: If no response by 2-3 weeks, consider alternative therapies rather than prolonging ACTH 7